Healthwell Acquisition Corp. I (HWEL) to Combine with Starton Therapeutics in $339M Deal
Healthwell Acquisition Corp. I (NASDAQ:HWEL) has entered into a definitive agreement to combine with clinical-stage biotech firm Starton at an enterprise value of $339 million. Paramus, New Jersey-based Starton is developing a line of treatments to improve efficacies in delivering drugs for certain types of cancer and mitigating the side effects of chemotherapy. The combinedRead More
To access this post, you must purchase 1 - User: Monthly Plan.